Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model.
In most clinical trials of intermittent androgen deprivation (IAD), the decision to stop androgen withdrawal is based on monitoring PSA levels, waiting for its drop to nadir. Based on in vitro pre-clinical studies, a modified 'on-off' schedule of short intervals of androgen deprivation, designated pulsed androgen deprivation (PAD), is proposed to destroy androgen dependent (AD) cells more gradually and to conserve their androgen-independent (AI) inhibitory potential for longer periods, resulting in an overall prolongation of time to hormone resistant progression.Prostate Cancer and Prostatic Diseases (2000) 3, 280-282
Pantuck
A J
AJ
Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA, USA.
Zismon
A
A
Tso
C-L
CL
Belldegrun
A S
AS